文献速递神经康复

左旋多巴辅助卒中康复:随机对照试验系统综述与荟萃分析

Levodopa-Based Therapy in Stroke Rehabilitation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Neurorehabil Neural Repair · 2026-04-03

该系统综述与荟萃分析纳入7项随机对照试验共1257例接受康复治疗的卒中成人患者,比较左旋多巴与安慰剂的效果。结果显示左旋多巴对运动功能、情绪和认知均无显著改善,不支持在常规卒中康复中常规使用多巴胺能增强治疗。

要点

  • 左旋多巴辅助治疗对卒中后运动功能恢复无显著获益。
  • 对情绪和认知功能同样未见显著改善。
  • 不建议在机制性或生物标志物分层试验之外常规使用。

核心结论

  • 左旋多巴为基础的治疗在卒中康复期间未改善运动、认知或情绪结局。
  • 多巴胺能增强不应在机制性或生物标志物分层试验之外常规使用。

研究设计与样本

  • 遵循PRISMA和Cochrane指南的系统综述与荟萃分析,检索PubMed、Embase和CENTRAL至2025年10月。
  • 纳入比较左旋多巴与安慰剂的随机对照试验,对象为接受康复治疗的卒中成人。
  • 共纳入7项随机对照试验,1257名参与者,平均年龄62-73岁。

主要发现

  • 左旋多巴对运动功能无显著影响(SMD: 0.01;95% CI: -0.10至0.13;I2 = 0%)。
  • 左旋多巴对情绪无显著影响(SMD: -0.10;95% CI: -0.30至0.10;I2 = 3%)。
  • 左旋多巴对认知无显著影响(SMD: -0.05;95% CI: -0.29至0.19;I2 = 0%)。
  • 敏感性分析证实结果稳定。

关键数值与推荐

  • 主要结局为采用经验证量表(如Fugl-Meyer评估)评估的运动恢复。
  • 次要结局包括情绪和认知功能。
  • 合并标准化均数差采用随机效应模型并以Hartung-Knapp-Sidik-Jonkman法调整。

临床怎么用

  • 不应将左旋多巴作为卒中康复的常规辅助治疗。
  • 左旋多巴的应用应限于机制性或生物标志物分层的临床试验情境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundThe dopaminergic system plays a key role in neuroplasticity and motor learning, suggesting that levodopa can enhance recovery after stroke. However, the clinical evidence is inconsistent. This systematic review and meta-analysis aimed to provide a definitive synthesis of randomized controlled trials (RCTs) that evaluated levodopa-based therapy as an adjunct to stroke rehabilitation.MethodsFollowing PRISMA and Cochrane guidelines, we systematically searched PubMed, Embase, and CENTRAL from inception to October 2025 for RCTs comparing levodopa with placebo in adults who had experienced a stroke and were undergoing rehabilitation. The primary outcome was motor recovery, which was assessed using validated scales (eg, Fugl-Meyer Assessment). Secondary outcomes included mood and cognitive function. Pooled standardized mean differences (SMDs) were calculated using a random-effects model with the Hartung-Knapp-Sidik-Jonkman adjustment.ResultsSeven RCTs comprising 1257 participants (mean age, 62-73 years) met the inclusion criteria. Levodopa had no significant effect on motor function compared with placebo (SMD: 0.01; 95% CI: -0.10 to 0.13; I2 = 0%), mood (SMD: -0.10; 95% CI: -0.30 to 0.10; I2 = 3%), or cognition (SMD: -0.05; 95% CI: -0.29 to 0.19; I2 = 0%). Sensitivity analyses confirmed the stability of the results.ConclusionsLevodopa-based therapy does not improve motor, cognitive, or mood outcomes during stroke rehabilitation. These findings close a long-standing question and indicate that dopaminergic augmentation should not be used routinely outside of mechanistic or biomarker-stratified trials.

来源:Neurorehabil Neural Repair,查看原文。版权归原作者所有。

引用

  1. Bena Nnang JY, Foncha FML, Fodop SGJ, et al. Levodopa-Based Therapy in Stroke Rehabilitation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Neurorehabil Neural Repair. 2026. PMID: 41933896. doi:10.1177/15459683261432098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。